Second-Generation Therapy for Retinal Vascular Diseases: More Than Meets the Eye

Second-Generation Therapy for Retinal Vascular Diseases: More Than Meets the Eye is organized by Postgraduate Institute for Medicine (PIM).

Start Date: March 14 2025
End Date: March 14 2026

Description:
The potential for extended durability is just the tip of the iceberg when considering the use of faricimab or aflibercept 8 mg. In this point-counterpoint activity, experts will get beneath the surface to discuss factors that can be used to refine and individualize treatment choice and retreatment decisions with the use of second-generation therapies. This includes differences in their mechanisms of action, clinical trial designs, effects on clinical biomarkers of disease activity, and (in some cases) the potential to reverse disease.

Educational Objectives:
Upon completion of this activity, participants should be able to:

• Compare the efficacy of second-generation therapies for retinal vascular diseases in terms of impact on anatomic markers of disease
• Discuss differences in the clinical trial designs that can affect outcome interpretation regarding second-generation therapies indicated for retinal vascular diseases
• Devise appropriate treatment plans for patients with treatment-naïve or previously treated neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion based on the latest evidence.